نتایج جستجو برای: bev

تعداد نتایج: 754  

Journal: :Journal of virology 1987
E Teyssedou R Magar D M Justewicz J Lecomte

Preparation of monoclonal antibodies to bovine virus diarrhea virus (BVDV) yielded some hybridoma cells that secreted monoclonal antibodies against the Madin-Darby bovine kidney cells. The anti-cellular monoclonal antibodies reacted with other bovine cells (bovine turbinate and testicle) but not with cell lines derived from other animal species. Subclones derived from one hybridoma partially bl...

2017
H. M. Earl L. Hiller J. A. Dunn C. Blenkinsop L. Grybowicz A.-L. Vallier I. Gounaris J. E. Abraham L. Hughes-Davies K. McAdam S. Chan R. Ahmad T. Hickish D. Rea C. Caldas J. M. S. Bartlett D. A. Cameron E. Provenzano J. Thomas R. L. Hayward

Background The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review. Patients and methods Patients wer...

2011
Ana M. Maestre Ana Garzón Dolores Rodríguez

Toroviruses are gastroenteritis causing agents that infect different animal species and humans. To date, very little is known about how toroviruses cause disease. Here, we describe for the first time that the prototype member of this genus, the equine torovirus Berne virus (BEV), induces apoptosis in infected cells at late times postinfection. Observation of BEV infected cells by electron micro...

2003
Stephen Eaves James Eaves

This paper compares the manufacturing and refueling costs of a Fuel-Cell Vehicle (FCV) and a Battery Electric Vehicle (BEV) using an automobile model reflecting the largest segment of light-duty vehicles. We use results from widely-cited government studies to compare the manufacturing and refueling costs of a BEV and a FCV capable of delivering 135 horsepower and driving approximately 300 miles...

2018
Shiqian Han Yuanduo Hong Tingting Liu Na Wu Zhijia Ye

Objectives To investigate the efficacy and safety of Bevacizumab (Bev) used in combination with paclitaxel and carboplatin (PC), compared with PC alone in patients with advanced non-small-cell lung cancer (NSCLC). Materials and Methods We searched the PubMed, EMBASE, Cochrane Central Register of Controlled Trials and Chinese Biomedical Literature electronic databases, to identify randomized c...

2015
R. Mkahl

Batteries of electric vehicles (BEV) are becoming more attractive with the advancement of new battery technologies and promotion of electric vehicles. BEV batteries are recharged on board vehicles using either the grid (G2V for Grid to Vehicle) or renewable energies in a stand-alone application (H2V for Home to Vehicle). This paper deals with the modeling, sizing and control of a photovoltaic s...

Journal: :Molecular cancer therapeutics 2007
Hung Huynh Ching Ching Melissa Teo Khee Chee Soo

Ovarian cancer is the leading cause of death from gynecologic cancer. Often, the disease has spread beyond the ovary to involve the peritoneal cavity and causes ascites. Whereas mammalian target of rapamycin (mTOR) functions to regulate protein translation, cell cycle progression, and metastasis, vascular endothelial growth factor promotes tumor angiogenesis, ascites formation, and metastasis i...

2017
Hannah Schneider Birthe Lohmann Hans-Georg Wirsching Kathy Hasenbach Elisabeth J. Rushing Karl Frei Martin Pruschy Ghazaleh Tabatabai Michael Weller

The poor prognosis associated with advanced age in patients with glioblastoma remains poorly understood. Glioblastoma in the elderly has been particularly associated with vascular endothelial growth factor (VEGF)-dependent angiogenesis, and early uncontrolled studies suggested that the anti-angiogenic agent bevacizumab (BEV), an antibody to VEGF, might be preferentially active in this patient p...

2012
M. Huylebrouck S. Lv J. Duerinck A. Van Binst I. Salmon J. De Greve O. De Witte S. Luce A. Michotte J. D'Haens B. Neyns

Background. Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated activity against recurrent high-grade gliomas (HGG) in phase II clinical trials. Patients and Methods. Data were collected from patients with recurrent HGG who initiated treatment with BEV outside a clinical trial protocol at two Belgian university hospitals. Results. 19 patients...

2017
Stephanie J. Blocker Kirk A. Douglas Lisa Anne Polin Helen Lee Bart S. Hendriks Enxhi Lalo Wei Chen Anthony F. Shields

Liposomes (LP) deliver drug to tumors due to enhanced permeability and retention (EPR). LP were labeled with 64Cu for positron emission tomography (PET) to image tumor localization. Bevacizumab (bev), a VEGF targeted antibody, may modify LP delivery by altering tumor EPR and this change can also be imaged. Objective: Assess the utility of 64Cu-labeled LP for PET in measuring altered LP delivery...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید